Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential

(2015) Erika M. Yazawa et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

(2014) J. Yuan et al.   Cancer Immunology Research

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Immunomodulatory therapy for melanoma: Ipilimumab and beyond

(2013) Margaret K. Callahan et al.   CLINICS IN DERMATOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis

(2012) A. Facciabene et al.   CANCER RESEARCH

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

Modulation of Immunity by Antiangiogenic Molecules in Cancer

(2012) Magali Terme et al.   Clinical & Developmental Immunology

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

(2012) Helene Pere et al.   OncoImmunology

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

(2011) Arcadi Cipponi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

(2011) A. A. Tarhini et al.   CLINICAL CANCER RESEARCH

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

(2011) Andrea Facciabene et al.   NATURE

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays

(2009) Janice M. Mehnert et al.   HUMAN PATHOLOGY

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

(2009) Marianna Sabatino et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

(2009) A. Craig Lockhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma

(2008) Domingo G. Perez et al.   CANCER

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

(2008) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

(2008) Sergio A. Quezada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

(2007) Ronald J Buckanovich et al.   NATURE MEDICINE